[Platelet adhesion mediated by von Willebrand factor in patients with premature coronary artery disease]

S D Okhota1, S G Kozlov1, Yu N Avtaeva1

  • 1Chazov National Medical Research Center of Cardiology.

Kardiologiia
|April 16, 2023
PubMed

Insights

Platelet adhesion mediated by von Willebrand factor (VWF) is heightened in premature ischemic heart disease (IHD). Blocking VWF-platelet interaction significantly reduces adhesion, suggesting VWF

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Pathophysiology

Context:

  • Premature ischemic heart disease (IHD) affects younger individuals, necessitating research into its underlying mechanisms.
  • Platelet function and interactions, particularly involving von Willebrand factor (VWF), are critical in cardiovascular health.
  • Understanding platelet adhesion dynamics is crucial for identifying novel therapeutic targets in IHD.

Purpose:

  • To investigate the role of von Willebrand factor (VWF)-mediated platelet adhesion in the pathogenesis of premature ischemic heart disease (IHD).
  • To compare platelet adhesion patterns between patients with premature IHD and a control group without IHD.
  • To assess the impact of inhibiting the VWF-platelet interaction on adhesion levels in both patient groups.

Summary:

  • Platelet adhesion to collagen under high shear rates was significantly reduced when VWF-GPIb interaction was blocked in premature IHD patients compared to controls.
  • A decrease in platelet adhesion exceeding 62.8% after blocking GPIb receptors was associated with an increased likelihood of premature IHD.
  • These findings suggest that excessive VWF-platelet interaction contributes to the development of premature IHD.

Impact:

  • Provides evidence for the significant contribution of VWF-mediated platelet adhesion to premature IHD.
  • Highlights the potential of targeting VWF-platelet interactions as a therapeutic strategy for preventing or treating premature IHD.
  • Offers a potential biomarker (reduced adhesion decrease after GPIb blockade) for identifying individuals at higher risk for premature IHD.

Related Concept Videos

Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.7K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
18
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.6K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
573
Structure and Function of Platelets01:18

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
1.3K
Intracellular Signaling Affects Focal Adhesions01:17

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
2.7K